Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD study of ACT-1004-1239 in healthy male subjects
NCT03869320Phase 1Completed
- Sponsor
- Idorsia
- Start
- Mar 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ACT-1004-1239 in multiple sclerosis (MS) (4 arms), sponsored by Idorsia. Primary endpoint: Number of patients with treatment-emergent (serious) adverse events up to 6 weeks. Started Mar 2019; status: completed.
02
Drugs
ACT-1004-1239
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03869320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03869320.